Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance

British Journal of Cancer

Volumn 109, Issue 9, 2013, Pages 2356-2367

  Kaliszczak, M ^a   Patel, H ^a   Kroll, S H B ^a   Carroll, L ^a   Smith, G ^a   Delaney, S ^a   Heathcote, D A ^a   Bondke, A ^a   Fuchter, M J ^a   Coombes, R C ^a   Barrett, A G M ^a   Ali, S ^a   Aboagye, E O ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

biomarkers; CDK; MDR; pharmacology; tumour

Indexed keywords

3' FLUOROTHYMIDINE F 18; ABC TRANSPORTER; ABC TRANSPORTER G1; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; ICEC 0782; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN MCL 1; PYRAZOLO[1,5 A ]PYRIMIDINE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL STRAIN HCT116; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG PENETRATION; DRUG RESISTANCE; DRUG UPTAKE; ENZYME SPECIFICITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; XENOGRAFT;

EID: 84887026442     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.584     Document Type: Article

References (51)

1. Aleem E, Kiyokawa H, Kaldis P (2005) Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat Cell Biol 7(8): 831-836.
2. Ali S, Heathcote DA, Kroll SH, Jogalekar AS, Scheiper B, Patel H, Brackow J, Siwicka A, Fuchter MJ, Periyasamy M, Tolhurst RS, Kanneganti SK, Snyder JP, Liotta DC, Aboagye EO, Barrett AG, Coombes RC (2009) The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res 69(15): 6208-6215.
3. Balin-Gauthier D, Delord JP, Rochaix P, Mallard V, Thomas F, Hennebelle I, Bugat R, Canal P, Allal C (2006) In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Cancer Chemother Pharmacol 57(6): 709-718.
4. Benson C, White J, De Bono J, O'Donnell A, Raynaud F, Cruickshank C, McGrath H, Walton M, Workman P, Kaye S, Cassidy J, Gianella-Borradori A, Judson I, Twelves C (2007) A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 96(1): 29-37.
5. Cai D, Latham Jr. VM, Zhang X, Shapiro GI (2006) Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 66(18): 9270-9280.
6. Cheng GM, To KK (2012) Adverse cell culture conditions mimicking the tumor microenvironment upregulate ABCG2 to mediate multidrug resistance and a more malignant phenotype. ISRN Oncol 2012: 746025.
7. Choong IC, Serafimova I, Fan J, Stockett D, Chan E, Cheeti S, Lu Y, Fahr B, Pham P, Arkin MR, Walker DH, Hoch U (2008) A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties. Bioorg Med Chem Lett 18(21): 5763-5765.
8. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258(5088): 1650-1654.
9. Cripe LD, Uno H, Paietta EM, Litzow MR, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Luger S, Tallman MS (2010) Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: A randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood 116(20): 4077-4085.
10. de la Motte S, Gianella-Borradori A (2004) Pharmacokinetic model of R-roscovitine and its metabolite in healthy male subjects. Int J Clin Pharmacol Ther 42(4): 232-239.
11. Didziapetris R, Japertas P, Avdeef A, Petrauskas A (2003) Classification analysis of P-glycoprotein substrate specificity. J Drug Target 11(7): 391-406.
12. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95(26): 15665-15670.
13. Fisher RP (2005) Secrets of a double agent: CDK7 in cell-cycle control and transcription. J Cell Sci 118(Pt 22): 5171-5180.
14. Fletcher JI, Haber M, Henderson MJ, Norris MD (2010) ABC transporters in cancer: More than just drug efflux pumps. Nat Rev Cancer 10(2): 147-156.
15. Harper JW, Elledge SJ (1998) The role of Cdk7 in CAK function, a retroretrospective. Genes Dev 12(3): 285-289.
16. Heathcote DA, Patel H, Kroll SH, Hazel P, Periyasamy M, Alikian M, Kanneganti SK, Jogalekar AS, Scheiper B, Barbazanges M, Blum A, Brackow J, Siwicka A, Pace RD, Fuchter MJ, Snyder JP, Liotta DC, Freemont PS, Aboagye EO, Coombes RC, Barrett AG, Ali S (2010) A novel pyrazolo[1,5-A]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration. J Med Chem 53(24): 8508-8522.
17. Higgins CF (2007) Multiple molecular mechanisms for multidrug resistance transporters. Nature 446(7137): 749-757.
18. Kaliszczak M, Antonow D, Patel KI, Howard P, Jodrell DI, Thurston DE, Guichard SM (2010) Optimization of the antitumor activity of sequencespecific pyrrolobenzodiazepine derivatives based on their affinity for ABC transporters. AAPS J 12(4): 617-627.
19. Kaliszczak M, Trousil S, Aberg O, Perumal M, Nguyen QD, Aboagye EO (2013) A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth. Br J Cancer 108(2): 342-350.
20. Kamath AV, Chong S, Chang M, Marathe PH (2005) P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats. Cancer Chemother Pharmacol 55(2): 110-116.
21. Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, Chen X, Gardner ER, Balis FM, Venkatesan AM, Steinberg SM, Fojo T, Bates SE (2011) A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res 17(3): 569-580.
22. Lapenna S, Giordano A (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8(7): 547-566.
23. Leyton J, Alao JP, Da Costa M, Stavropoulou AV, Latigo JR, Perumal M, Pillai R, He Q, Atadja P, Lam EW, Workman P, Vigushin DM, Aboagye EO (2006) In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 30-deoxy-30-[18F]fluorothymidine positron emission tomography. Cancer Res 66(15): 7621-7629.
24. Li Z, Graf N, Herrmann K, Junger A, Aichler M, Feuchtinger A, Baumgart A, Walch A, Peschel C, Schwaiger M, Buck A, Keller U, Dechow T (2012) FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy. Cancer Res 72(19): 5014-5024.
25. Lolli G, Johnson LN (2005) CAK-cyclin-dependent activating kinase: A key kinase in cell cycle control and a target for drugs?. Cell Cycle 4(4): 572-577.
26. Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205(2): 275-292.
27. Malumbres M, Barbacid M (2001) To cycle or not to cycle: A critical decision in cancer. Nat Rev Cancer 1(3): 222-231.
28. Meinhart A, Kamenski T, Hoeppner S, Baumli S, Cramer P (2005) A structural perspective of CTD function. Genes Dev 19(12): 1401-1415.
29. Nakagawa M, Schneider E, Dixon KH, Horton J, Kelley K, Morrow C, Cowan KH (1992) Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantroneresistant human MCF-7 breast cancer cells. Cancer Res 52(22): 6175-6181.
30. Nutley BP, Raynaud FI, Wilson SC, Fischer PM, Hayes A, Goddard PM, McClue SJ, Jarman M, Lane DP, Workman P (2005) Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse. Mol Cancer Ther 4(1): 125-139.
31. Palancade B, Bensaude O (2003) Investigating RNA polymerase II carboxylterminal domain (CTD) phosphorylation. Eur J Biochem 270(19): 3859-3870.
32. Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D, Seghezzi W, Paruch K, Dwyer MP, Doll R, Nomeir A, Windsor W, Fischmann T, Wang Y, Oft M, Chen T, Kirschmeier P, Lees EM (2010) Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 9(8): 2344-2353.
33. Pham AN, Wang J, Fang J, Gao X, Zhang Y, Blower PE, Sadee W, Huang Y (2009) Pharmacogenomics approach reveals MRP1 (ABCC1)-mediated resistance to geldanamycins. Pharm Res 26(4): 936-945.
34. Pines J (1991) Cyclins: Wheels within wheels. Cell Growth Differ 2(6): 305-310.
35. Pisaneschi F, Nguyen QD, Shamsaei E, Glaser M, Robins E, Kaliszczak M, Smith G, Spivey AC, Aboagye EO (2010) Development of a new epidermal growth factor receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core: Synthesis and biological evaluation. Bioorg Med Chem 18(18): 6634-6645.
36. Prelich G (2002) RNA polymerase II carboxy-Terminal domain kinases: Emerging clues to their function. Eukaryot Cell 1(2): 153-162.
37. Robey RW, Medina-Perez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD, Bates SE (2001) Overexpression of the ATPbinding cassette half-Transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 7(1): 145-152.
38. Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SP, Doyle LA (1999) Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 91(5): 429-433.
39. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Hill K, Steinberg SM, Figg WD, Tompkins A, Arbuck SG, Sausville EA (1998) Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16(9): 2986-2999.
40. Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24(11): 1770-1783.
41. Shen DW, Fojo A, Chin JE, Roninson IB, Richert N, Pastan I, Gottesman MM (1986) Human multidrug-resistant cell lines: Increased mdr1 expression can precede gene amplification. Science 232(4750): 643-645.
42. Sherr CJ (1994) G1 phase progression: Cycling on cue. Cell 79(4): 551-555.
43. Sherr CJ (1996) Cancer cell cycles. Science 274(5293): 1672-1677.
44. Spoelstra EC, Dekker H, Schuurhuis GJ, Broxterman HJ, Lankelma J (1991) P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport. Biochem Pharmacol 41(3): 349-359.
45. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5(3): 219-234.
46. Tong WG, Chen R, Plunkett W, Siegel D, Sinha R, Harvey RD, Badros AZ, Popplewell L, Coutre S, Fox JA, Mahadocon K, Chen T, Kegley P, Hoch U, Wierda WG (2010) Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol 28(18): 3015-3022.
47. Tumber A, Collins LS, Petersen KD, Thougaard A, Christiansen SJ, Dejligbjerg M, Jensen PB, Sehested M, Ritchie JW (2007) The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol 60(2): 275-283.
48. Varma MV, Sateesh K, Panchagnula R (2005) Functional role of P-glycoprotein in limiting intestinal absorption of drugs: Contribution of passive permeability to P-glycoprotein mediated efflux transport. Mol Pharm 2(1): 12-21.
49. Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1(3): 1112-1116.
50. Wild R, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S, Luo FR, Camuso A, McGlinchey K, Rose WC (2006) Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. Mol Cancer Ther 5(1): 104-113.
51. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102(11): 1555-1577.